Inhibition of the human mitochondrial ClpP protease as a novel strategy against multiple myeloma

被引：0

作者：

Patrone, M. ^{[1
]}

Di Pisa, F. ^{[1
]}

Tosatto, L. ^{[2
]}

Swuec, P. ^{[2
]}

Perini, T. ^{[1
]}

Resnati, M. ^{[1
]}

Del Grosso, Erika ^{[3
]}

Yudin, A. K. ^{[4
]}

Schimmer, A. D. ^{[5
]}

Cenci, S. ^{[1
]}

Coscia, F. ^{[2
]}

Degano, M. ^{[1
]}

机构：

[1] Univ Vita Salute San Raffaele, Via Olgettina 58, I-20132 Milan, Italy

[2] Human Technopole, Viale Rita Levi Montalcini 1, I-20157 Milan, Italy

[3] Univ Piemonte Orientale, Dipartimento Sci Farmaco, Lgo Donegani 2, I-28100 Novara, Italy

[4] Univ Toronto, Dept Chem, Davenport Res Labs, 80 St George St, Toronto, ON M5S 3H6, Canada

[5] Univ Hlth Network, Princess Margaret Canc Ctr, 610 Univ Ave, Toronto, ON M5G 2M9, Canada

来源：

ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

页数：1

共 50 条

[31] RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma
Lee, Hans C.
Wang, Hua
Baladandayuthapani, Veerabhadran
Lin, Heather
He, Jin
Jones, Richard J.
Kuiatse, Isere
Gu, Dongmin
Wang, Zhiqiang
Ma, Wencai
Lim, John
O'Brien, Sean
Keats, Jonathan
Yang, Jing
Davis, Richard E.
Orlowski, Robert Z.
BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (01) : 80 - 94
[32] Protease inhibition by novel fluoropeptidomimetics: A mechanism-based design strategy
Kotra, Lakshmi P.
Annedi, Subhash C.
Majumder, Kanchana
Wei, Lianhu
Samson, Sheeba
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 231
[33] The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
Op, Melanie
Ribeiro, Sergio T.
Chavarria, Claire
De Gassart, Aude
Zaffalon, Lea
Martinon, Fabio
CELL DEATH & DISEASE, 2022, 13 (05)
[34] The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
Mélanie Op
Sérgio T. Ribeiro
Claire Chavarria
Aude De Gassart
Léa Zaffalon
Fabio Martinon
Cell Death & Disease, 13
[35] Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
Ortiz-Ruiz, Alejandra
Ruiz-Heredia, Yanira
Luz Morales, Maria
Aguilar-Garrido, Pedro
Garcia-Ortiz, Almudena
Valeri, Antonio
Barcena, Carmen
Garcia-Martin, Rosa Maria
Garrido, Vanesa
Moreno, Laura
Gimenez, Alicia
Angel Navarro-Aguadero, Miguel
Velasco-Estevez, Maria
Lospitao, Eva
Cedena, Maria Teresa
Barrio, Santiago
Martinez-Lopez, Joaquin
Linares, Maria
Gallardo, Miguel
CANCERS, 2021, 13 (07)
[36] The Pivotal Role of Glutaminolysis in Multiple Myeloma: Novel Strategies for Target Therapies Against Myeloma
Okabe, Seiichi
Tanaka, Yuko
Gotoh, Akihiko
BLOOD, 2021, 138
[37] Molecular sequelae of proteasome inhibition in human multiple myeloma cells
Mitsiades, N
Mitsiades, CS
Poulaki, V
Chauhan, D
Fanourakis, G
Gu, XS
Bailey, C
Joseph, M
Libermann, TA
Treon, SP
Munshi, NC
Richardson, PG
Hideshima, T
Anderson, KC
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) : 14374 - 14379
[38] Mitochondrial matrix protease ClpP agonists suppress breast cancer stem cell function by downregulating multiple stem cell regulatory mechanisms
Greer, Yoshimi E.
Hernandez, Lidia
Voeller, Donna
Chari, Raj
Tang, Binwu
Annunziata, Christina M.
Gilbert, Sam
Wakefield, Lalage
Iwanowicz, Edwin
Graves, Lee M.
Lipkowitz, Stanley
MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
[39] Targeted Inhibition of Myeloperoxidase (MPO): A New Therapeutic Strategy for the Treatment of Multiple Myeloma
Williams, Connor
Noll, Jacqueline
Harnas, Dylan
Parkinson, Hayley
Hewett, Duncan
Wyllie, Kaitlin
Cox, Thomas
Zannettino, Andrew
Vandyke, Kate
Panagopoulos, Vasilios
BLOOD, 2023, 142
[40] Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Kuhn, Deborah J.
Hunsucker, Sally A.
Chen, Qing
Voorhees, Peter M.
Orlowski, Marian
Orlowski, Robert Z.
BLOOD, 2009, 113 (19) : 4667 - 4676

← 1 2 3 4 5 →